# Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

> **NCT02706678** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma China, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Renal Transplant Recipients

## Interventions

- **DRUG:** Tacrolimus sustained-release capsule

## Key facts

- **NCT ID:** NCT02706678
- **Lead sponsor:** Astellas Pharma China, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-29
- **Primary completion:** 2012-08-01
- **Final completion:** 2012-08-01
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706678, "Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02706678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*